867 related articles for article (PubMed ID: 20332000)
1. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S
Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
Wiley JL; Marusich JA; Blough BE; Namjoshi O; Brackeen M; Akinfiresoye LR; Walker TD; Prioleau C; Barrus DG; Gamage TF
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110984. PubMed ID: 38417478
[TBL] [Abstract][Full Text] [Related]
4. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556.
Colodete DAE; Silva NR; Pedrazzi JFC; Fogaça MV; Cortez I; Del-Bel EA; Breuer A; Mechoulam R; Gomes FV; Guimarães FS
Behav Pharmacol; 2023 Jun; 34(4):213-224. PubMed ID: 37171460
[TBL] [Abstract][Full Text] [Related]
5. [Determination of 11 Cannabinoids in Cannabis sativa L. by Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF-MS)].
Tanaka R; Mizutani S; Kawamura M; Fuchino H; Kawahara N; Kikura-Hanajiri R
Yakugaku Zasshi; 2023; 143(4):411-418. PubMed ID: 37005243
[TBL] [Abstract][Full Text] [Related]
6. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.
Roser P; Gallinat J; Weinberg G; Juckel G; Gorynia I; Stadelmann AM
Eur Arch Psychiatry Clin Neurosci; 2009 Aug; 259(5):284-92. PubMed ID: 19224107
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.
Fischedick J; Van Der Kooy F; Verpoorte R
Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):201-7. PubMed ID: 20118579
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the cataleptic effect of tetrahydrocannabinol by other constituents of Cannabis sativa L.
Formukong EA; Evans AT; Evans FJ
J Pharm Pharmacol; 1988 Feb; 40(2):132-4. PubMed ID: 2897447
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
10. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Strategies for Rare Cannabinoids Derived from
Nguyen GN; Jordan EN; Kayser O
J Nat Prod; 2022 Jun; 85(6):1555-1568. PubMed ID: 35648593
[TBL] [Abstract][Full Text] [Related]
13. Direct Quantitation of Phytocannabinoids by One-Dimensional
Dadiotis E; Mitsis V; Melliou E; Magiatis P
Molecules; 2022 May; 27(9):. PubMed ID: 35566314
[TBL] [Abstract][Full Text] [Related]
14. Determination of cannabinoids in human cerumen samples by use of UPLC-MS/MS as a potential biomarker for drug use.
Christodoulou MC; Constantinou MS; Louppis AP; Christou A; Stavrou IJ; Kapnissi-Christodoulou CP
J Pharm Biomed Anal; 2023 Jul; 231():115412. PubMed ID: 37087774
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
16. [Quantitative analysis and pharmaco-toxicity of cannabinoids in commercially available cannabis seeds].
Matsunaga T; Watanabe K; Yoshimura H; Yamamoto I
Yakugaku Zasshi; 1998 Sep; 118(9):408-14. PubMed ID: 9779001
[TBL] [Abstract][Full Text] [Related]
17. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
18. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol attenuates delta 9-tetrahydrocannabinol-like discriminative stimulus effects of cannabinol.
Hiltunen AJ; Järbe TU
Eur J Pharmacol; 1986 Jun; 125(2):301-4. PubMed ID: 3017729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
